Figure 2.

Effects of lenalidomide on plasmacytoid dendritic cell maturation. Human plasmacytoid dendritic cells (pDCs) were incubated for 24 h with the indicated concentrations of lenalidomide (LEN), bortezomib (BOR), or vehicle in the presence of 3 μM CpG-ODN 2216. (A) After 24 h, CD86 expression on pDCs was analyzed using flow cytometry. Data were quantified as the mean fluorescence intensity (MFI), which was calculated by subtraction of the MFI for the isotype control from the MFI for cells stained with CD86 mAb. Data are shown as means ± SEMs of six independent donors. (B) CD4⁺ T cells were stimulated for 7 days with allogeneic pDCs pretreated with CpG, CpG + 1 μM LEN, or CpG + 30 nM bortezomib for 24 h. After culture, cells were quantitated by trypan blue dye-exclusion. Data are shown from four independent sets of experiments. Statistical significance was determined using paired Student’s t-tests (*=p<0.05, **=p<0.01; p-values were calculated for each concentration of LEN or bortezomib versus vehicle control).

Abbreviation: N.E., not evaluated.